Anaesthetic Formulation Using Carbon Quantum Dots for Sustained Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing local anesthetic agents lack improvements in pharmacokinetic and pharmacodynamic properties, leading to a need for longer-lasting pain relief without the risks associated with opioid treatments.
Innovation Solution
A pharmaceutical composition comprising anesthetic agents like ropivacaine, bupivacaine, and carbon quantum dots, along with alkanolamines, provides a long-lasting anesthetic effect through increased water solubility and slow-release mechanisms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional local anesthetic agents are used, then pain relief is achieved, but the duration of action is insufficient and opioid treatments are required
Solution Approach 1:
The patent modifies the pharmacokinetic parameters of local anesthetic agents by combining them with carbon quantum dots and alkanolamines. This formulation changes the release rate and duration of action, extending pain relief from conventional short duration to prolonged duration (at least 1 hour, preferably 2-12 hours), thereby eliminating the need for opioid rescue medications and their associated risks
Solution Approach 2:
The invention creates a composite pharmaceutical formulation combining local anesthetic agents with carbon quantum dots and alkanolamines. This composite structure enables sustained release and prolonged duration of action through the synergistic effects of the components, achieving long-lasting pain relief without requiring additional opioid interventions
2Reliability
If local anesthetic agents are used for surgical anesthesia, then pain relief is provided, but the pharmacokinetic properties can be improved
Solution Approach 1:
Carbon quantum dots serve as an intermediary carrier that facilitates sustained release of local anesthetic agents. The quantum dots interact with the anesthetic molecules and control their release kinetics, improving pharmacokinetic properties by extending the duration of action while maintaining reliable and predictable drug delivery profiles
Solution Approach 2:
The formulation ensures continuous and sustained action of the local anesthetic agent through the carbon quantum dot-alcanolamine complex. This continuous release mechanism maintains reliable pharmacokinetic properties over an extended period, preventing the need for repeated dosing or adjunctive opioid treatments
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition offers prolonged pain relief, reducing the need for opioid treatments and minimizing associated complications, suitable for various administration routes including topical and injection methods.
Implementation Method 1
Carbon quantum dots are a class of nanomaterials that have attracted attention because of their low toxicity, water solubility and fluorescence
Implementation Method 2
They have the similar mechanism of action in which they cause a reversible inhibition of sodium ion influx, which blocks impulse conduction in nerve fibers
Data Source
AI summary
The present invention is within the technical field of pain-relief and relates to a pharmaceutical composition comprising at least one anesthetic agent selected from the group consisting of ropivacaine, bupivacaine, etidocaine, levobupivacaine, lidocaine, lignocaine, mepivacaine, articaine, dibucaine, levobupivacaine, prilocaine, benzocaine, chloroprocaine, cocaine, procaine, proparacaine, tetracaine and any pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof; at least one alkanolamine selected from the group consisting of triethanolamine, tripropanolamine and trimethanolamine; water; and optionally a pharmaceutically acceptable diluent, carrier and/or excipient. The present disclosure furthermore relates to the use of the composition for providing pain-relief, a method of treatment, a method of producing said pharmaceutical composition as well as a carbon quantum dot formed from components of the pharmaceutical composition.